Amgen Com (AMGN) Shareholder Pinebridge Investments LP Raised Stake by $7.13 Million as Market Valuation Declined; Gilman Hill Asset Management Decreased Holding in Pfizer (PFE) as Market Valuation Declined

Amgen Inc. (NASDAQ:AMGN) Logo

Gilman Hill Asset Management Llc decreased its stake in Pfizer Inc (PFE) by 14.24% based on its latest 2019Q1 regulatory filing with the SEC. Gilman Hill Asset Management Llc sold 16,462 shares as the company’s stock declined 1.32% while stock markets rallied. The institutional investor held 99,123 shares of the health care company at the end of 2019Q1, valued at $4.21 million, down from 115,585 at the end of the previous reported quarter. Gilman Hill Asset Management Llc who had been investing in Pfizer Inc for a number of months, seems to be less bullish one the $236.90 billion market cap company. The stock decreased 0.93% or $0.4 during the last trading session, reaching $42.67. About 15.71 million shares traded. Pfizer Inc. (NYSE:PFE) has risen 14.75% since June 11, 2018 and is uptrending. It has outperformed by 10.32% the S&P500. Some Historical PFE News: 09/04/2018 – Pfizer Canada and MaRS Innovation Partner to Convert Great Science into Solutions to Benefit Canadians’ Health; 15/05/2018 – Rexahn Pharm: SMC Confirmed Combination of RX-3117 and Abraxane Is Safe and Well Tolerated; 14/03/2018 – Global Acromegaly and Gigantism Drugs Market 2018-2022 – Key Vendors are lpsen, Novartis & Pfizer – ResearchAndMarkets.com; 03/04/2018 – PFIZER INC PFE.N SAYS ALLOGENE WILL RECEIVE RIGHTS TO ONE CLINICAL ASSET FROM SERVIER CALLED UCART19; 19/03/2018 – U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Ca; 25/05/2018 – Australian anti-trust watchdog loses appeal against Pfizer over Lipitor sales; 03/04/2018 – PFIZER AND ALLOGENE THERAPEUTICS ENTER INTO ASSET CONTRIBUTION AGREEMENT FOR PFIZER’S ALLOGENEIC CAR T IMMUNO-ONCOLOGY PORTFOLIO; 09/04/2018 – Pfizer Canada and MaRS Innovation Partner to Convert Great Science into Solutions to Benefit Canadians’ Health; 22/05/2018 – A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+; 20/04/2018 – Biogen boosts investment in neurology with $1 bln Ionis deal

Pinebridge Investments Lp increased its stake in Amgen Inc Com (AMGN) by 17.78% based on its latest 2019Q1 regulatory filing with the SEC. Pinebridge Investments Lp bought 37,739 shares as the company’s stock declined 10.11% while stock markets rallied. The hedge fund held 250,010 shares of the biological products (no diagnostic substances) company at the end of 2019Q1, valued at $47.50 million, up from 212,271 at the end of the previous reported quarter. Pinebridge Investments Lp who had been investing in Amgen Inc Com for a number of months, seems to be bullish on the $106.51B market cap company. The stock decreased 0.55% or $0.96 during the last trading session, reaching $174.62. About 2.11 million shares traded. Amgen Inc. (NASDAQ:AMGN) has declined 3.46% since June 11, 2018 and is downtrending. It has underperformed by 7.89% the S&P500. Some Historical AMGN News: 01/05/2018 – The deal excludes a competing medicine made by Amgen from Express Scripts’ National Preferred Formulary Plan; 14/05/2018 – Evenity (romosozumab; Amgen/UCB/Astellas) Drug Overview Report 2018 – ResearchAndMarkets.com; 01/05/2018 – Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable p; 16/05/2018 – AMGEN GETS EC APPROVAL FOR REPATHA® (EVOLOCUMAB) TO PREVENT HEA; 29/03/2018 – FDA SAYS BLINCYTO CARRIES A BOXED WARNING; 23/03/2018 – AMGEN GETS POSITIVE CHMP OPINION RECOGNIZING REPATHA® (EVOLOCUM; 23/03/2018 – AMGEN INC – RECOMMENDED FOR APPROVAL FOR SAME INDICATIONS AS HERCEPTIN; 18/04/2018 – Amgen at American Academy of Neurology Meeting Apr 24; 10/03/2018 – Regeneron/Sanofi offer new Praluent pricing to break reimbursement logjam; 17/05/2018 – U.S. FDA approves Amgen drug for prevention of migraines

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Streetinsider.com which released: “Pfizer (PFE) Phase 3 Trial of LYRICA in PGTC Seizures Did Not Meet its Primary Endpoint – StreetInsider.com” on May 24, 2019, also Learnbonds.com with their article: “Pfizer Inc. (NYSE:PFE) Buys BIND’s Assets – LearnBonds” published on August 25, 2016, 247Wallst.com published: “Pfizer Overtakes Apple as Most Shorted Dow Stock – 24/7 Wall St.” on May 28, 2019. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Finance.Yahoo.com and their article: “Were Hedge Funds Right About Souring On Pfizer Inc. (PFE)? – Yahoo Finance” published on June 01, 2019 as well as Seekingalpha.com‘s news article titled: “Dividend Arbitrage For Pfizer – Seeking Alpha” with publication date: June 10, 2019.

Investors sentiment increased to 0.76 in Q1 2019. Its up 0.02, from 0.74 in 2018Q4. It improved, as 66 investors sold PFE shares while 763 reduced holdings. 125 funds opened positions while 501 raised stakes. 3.88 billion shares or 4.26% less from 4.05 billion shares in 2018Q4 were reported. Earnest Prtnrs Llc has invested 0% in Pfizer Inc. (NYSE:PFE). Financial Advisory Ser holds 0.22% or 26,508 shares. Blackrock holds 0.85% or 445.91 million shares. Van Hulzen Asset Lc accumulated 1.81% or 158,165 shares. Fort Washington Investment Advsr Oh owns 191,209 shares. Covington Investment Advsr holds 1.14% or 79,785 shares. Moreover, At Financial Bank has 0.1% invested in Pfizer Inc. (NYSE:PFE). Fincl Mgmt stated it has 6,085 shares or 0.1% of all its holdings. Horizon Limited Liability Com has 0.13% invested in Pfizer Inc. (NYSE:PFE). Thompson Rubinstein Invest Or holds 98,293 shares or 1.34% of its portfolio. Amer Registered Inv Advisor owns 48,723 shares or 1.15% of their US portfolio. Robeco Institutional Asset Mngmt Bv holds 1.15% or 7.38M shares in its portfolio. Rwc Asset Mngmt Limited Liability Partnership has 48,892 shares for 0.09% of their portfolio. Zevin Asset Management Ltd Liability Co accumulated 0.13% or 9,210 shares. Bonness Enterprises holds 78,608 shares or 2.17% of its portfolio.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on July, 30. They expect $0.78 earnings per share, down 3.70% or $0.03 from last year’s $0.81 per share. PFE’s profit will be $4.33B for 13.68 P/E if the $0.78 EPS becomes a reality. After $0.85 actual earnings per share reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -8.24% negative EPS growth.

Gilman Hill Asset Management Llc, which manages about $250.11 million and $284.60M US Long portfolio, upped its stake in Tanger Factory Outlet Ctrs I (NYSE:SKT) by 23,720 shares to 205,107 shares, valued at $4.30 million in 2019Q1, according to the filing. It also increased its holding in Schlumberger Ltd (NYSE:SLB) by 12,861 shares in the quarter, for a total of 120,230 shares, and has risen its stake in At&T Inc (NYSE:T).

Since January 30, 2019, it had 0 insider purchases, and 1 insider sale for $1.81 million activity.

Pinebridge Investments Lp, which manages about $38.23 billion and $4.93 billion US Long portfolio, decreased its stake in Fifth Third Bancorp Com (NASDAQ:FITB) by 36,824 shares to 1.29 million shares, valued at $32.53M in 2019Q1, according to the filing. It also reduced its holding in Dsw Inc Cl A (NYSE:DSW) by 28,446 shares in the quarter, leaving it with 56,076 shares, and cut its stake in Conagra Brands Inc Com (NYSE:CAG).

Since February 7, 2019, it had 0 buys, and 1 insider sale for $380,000 activity.

More notable recent Amgen Inc. (NASDAQ:AMGN) news were published by: Nasdaq.com which released: “Health Care Sector Update for 05/31/2019: IOVA, MYOV, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” on May 31, 2019, also Nasdaq.com with their article: “Amgen (AMGN) Dips More Than Broader Markets: What You Should Know – Nasdaq” published on May 31, 2019, Seekingalpha.com published: “NeuClone to launch clinical development of Stelara biosimilar – Seeking Alpha” on May 15, 2019. More interesting news about Amgen Inc. (NASDAQ:AMGN) were released by: Nasdaq.com and their article: “Was ASCO Quieter for Big Drug/Biotech Stocks This Year? – Nasdaq” published on June 06, 2019 as well as 247Wallst.com‘s news article titled: “Credit Suisse Calls Out Amgen as Its Key Cancer Winner From ASCO – 24/7 Wall St.” with publication date: June 04, 2019.

Investors sentiment decreased to 0.88 in 2019 Q1. Its down 0.11, from 0.99 in 2018Q4. It fall, as 70 investors sold AMGN shares while 539 reduced holdings. 131 funds opened positions while 405 raised stakes. 457.12 million shares or 8.22% less from 498.05 million shares in 2018Q4 were reported. Jag Management Limited Company owns 1,100 shares for 0.03% of their portfolio. Employees Retirement Sys Of Texas holds 0.17% or 60,266 shares. Moreover, Metropolitan Life Insurance Commerce New York has 0.02% invested in Amgen Inc. (NASDAQ:AMGN) for 23,563 shares. Beacon Group Inc owns 25,795 shares. Commonwealth Bancorporation Of Australia accumulated 0.15% or 83,612 shares. Ellington Mgmt Grp Ltd Liability Corporation stated it has 0.1% of its portfolio in Amgen Inc. (NASDAQ:AMGN). Kbc Grp Nv has 0.35% invested in Amgen Inc. (NASDAQ:AMGN). Raymond James Financial Ser Advsr has invested 0.19% in Amgen Inc. (NASDAQ:AMGN). 16,726 are owned by Pitcairn Company. Tokio Marine Asset Management Commerce Limited owns 1,557 shares for 0.05% of their portfolio. Private Ocean Ltd Liability Corporation owns 1,182 shares or 0.06% of their US portfolio. Greylin Mangement holds 0.54% or 12,732 shares in its portfolio. Glenmede Trust Na owns 815,017 shares or 0.7% of their US portfolio. Sns Gp Llc owns 8,107 shares for 0.34% of their portfolio. Conning has invested 1.4% in Amgen Inc. (NASDAQ:AMGN).

Amgen Inc. (NASDAQ:AMGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.